互联药物输送设备市场规模、份额和成长分析（按产品类型、技术、应用、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，连网药物输送设备市场规模将达到 74.7 亿美元，到 2025 年将达到 92.9 亿美元，到 2033 年将达到 529.2 亿美元，在预测期（2026-2033 年）内，复合年增长率将达到 24.3%。

全球互联药物输送设备市场正经历显着成长，这主要得益于数位健康解决方案的日益普及和个人化医疗需求的不断增长。这些设备可为患者、医疗服务提供者和看护者提供即时数据追踪、提醒和通知，有助于改善药物管理和提升患者疗效。物联网、人工智慧和云端运算等先进技术的整合正在透过增强患者参与度和实现远端监测来改变医疗保健格局。随着全球医疗系统采用数位转型策略并持续优先考虑以患者为中心的护理，该市场已做好充分准备迎接显着扩张，这反映了医疗服务模式向更有效率、更有效的转变。

互联药物输送设备市场驱动因素

互联药物输送设备市场的主要驱动因素是对互联个人化医疗解决方案日益增长的需求。这些创新设备具有许多优势，包括远端患者监护、即时数据采集和提高用药依从性。它们使医疗专业人员能够有效追踪患者的健康状况，调整治疗方案，并提供个人化护理。将互联技术融入药物输送系统，可增强患者参与度，并有助于改善治疗效果。此外，慢性病发病率的上升以及对先进药物输送系统的需求，也是推动该市场成长的关键因素。

互联药物传输设备市场面临的限制

互联药物传输设备市场面临的一大挑战是这些先进技术相关的高成本。无线连接和高级数据管理系统等功能的加入显着提高了设备的价格。这一经济障碍阻碍了设备的广泛应用，尤其是在资源匮乏地区和发展中地区，预算限制是关键考虑因素。在某些患者群体和医疗服务提供者中，互联药物输送设备的普及仍然受到价格和可及性问题的限制。解决这些成本相关的障碍，提高这些创新解决方案的可负担性，对于促进更广泛的接受度和刺激市场成长至关重要。

互联药物传输设备市场趋势

互联药物输送设备市场正呈现出显着的趋势，即整合先进的数位技术。尤其是在呼吸治疗领域，智慧吸入器和其他连网设备的使用量激增。这些创新解决方案配备感测器和无线连接功能，能够全面监测患者的用药依从性、使用模式和剂量准确性。行动应用程式可为患者提供即时回馈和个人化建议，从而增强患者参与自身健康管理的积极性和自主性。这种向数据驱动型解决方案的转变不仅改善了治疗效果，还促进了更积极主动的患者照护模式，最终推动了互联药物输送设备市场的成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步
• 监管环境
• 专利分析
• 案例研究
• Start-Ups分析

全球互联药物输送设备市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 连接式吸入器
  • 定量吸入器（MDI）
  • 干粉吸入器（DPI）
• 网路注射装置
  • 可连接式自动喷射器
  • 可连接的笔式射出器
  • 连网穿戴注射器
• 网路监控设备
  • 智慧药丸
  • 智慧型贴片

全球互联药物输送设备市场规模（依技术及复合年增长率划分）（2026-2033 年）

• Bluetooth
• Wi-Fi
• 近距离场通讯（NFC）
• 其他的

全球互联药物输送设备市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 糖尿病
  • 胰岛素给药
• 气喘和慢性阻塞性肺病（COPD）
  • 支气管扩张剂给药
• 循环系统疾病
  • 抗凝血剂给药
• 其他的
  • 荷尔蒙补充疗法
  • 疼痛管理

全球互联药物输送设备市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院
  • 大型医院
  • 中小型医院
• 居家医疗环境
  • 个别患者
  • 看护者
• 诊所
  • 专科诊所
  • 一般诊所

全球互联药物输送设备市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Findair Sp. z oo（Poland）
• BIO CORP（France）
• Teva Pharmaceuticals Industries Ltd（Israel）
• Adherium Limited（New Zealand）
• West Pharmaceutical Services Inc.（USA）
• Aptar Pharma（USA）
• Ypsomed AG（Switzerland）
• Phillips-Medisize（USA）
• H&T Presspart Manufacturing Ltd（UK）
• Cohero Health, Inc.（USA）
• 3M Company（USA）
• Becton, Dickinson and Company（USA）
• Merck KGaA（Germany）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• Sanofi SA（France）
• F. Hoffmann-La Roche Ltd（Switzerland）

结论与建议

Connected Drug Delivery Devices Market size was valued at USD 7.47 Billion in 2024 and is poised to grow from USD 9.29 Billion in 2025 to USD 52.92 Billion by 2033, growing at a CAGR of 24.3% during the forecast period (2026-2033).

The global connected drug delivery devices market is witnessing notable growth, fueled by the rising adoption of digital health solutions and the demand for personalized healthcare. These devices provide real-time data tracking, along with reminders and notifications for patients, healthcare providers, and caregivers, which facilitates improved medication management and enhances patient outcomes. The incorporation of advanced technologies such as IoT, AI, and cloud computing is transforming the healthcare landscape by boosting patient engagement and enabling remote monitoring. As healthcare systems globally continue to adopt digital transformation strategies and emphasize patient-centric care, the market is well-positioned for significant expansion, reflecting a shift towards more efficient and effective healthcare delivery models.

Top-down and bottom-up approaches were used to estimate and validate the size of the Connected Drug Delivery Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Connected Drug Delivery Devices Market Segments Analysis

Global Connected Drug Delivery Devices Market is segmented by product type, technology, application, end-user and region. Based on product type, the market is segmented into connected inhalers, connected injection devices and connected monitoring devices. Based on technology, the market is segmented into bluetooth, wi-fi, near field communication (NFC) and others. Based on application, the market is segmented into diabetes, asthma & COPD, cardiovascular diseases and other. Based on end-user, the market is segmented into hospitals, homecare settings and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Connected Drug Delivery Devices Market

A significant driver of the connected drug delivery devices market is the growing need for personalized healthcare solutions that are interconnected. These innovative devices provide numerous advantages, including the capability for remote patient monitoring, real-time data collection, and enhanced medication adherence. They empower healthcare providers to effectively track patient health, modify treatment plans, and offer tailored care. The incorporation of connected technology into drug delivery systems bolsters patient engagement and fosters improved treatment outcomes. Furthermore, the rising incidence of chronic illnesses and the demand for sophisticated drug delivery systems play a crucial role in fueling the growth of this market.

Restraints in the Connected Drug Delivery Devices Market

A prominent challenge facing the connected drug delivery devices market is the elevated costs linked to these advanced technologies. The incorporation of features such as wireless connectivity and sophisticated data management systems significantly raises the prices of these devices. This financial barrier hinders widespread adoption, especially in low-resource settings and developing regions, where budget constraints are a critical consideration. Affordability and accessibility issues continue to restrict the uptake of connected drug delivery devices among specific patient demographics and healthcare providers. To foster broader acceptance and stimulate market growth, it will be crucial to address these cost-related obstacles and enhance the affordability of these innovative solutions.

Market Trends of the Connected Drug Delivery Devices Market

The Connected Drug Delivery Devices market is witnessing a significant trend towards the integration of advanced digital technologies, particularly the surge in the use of smart inhalers and other connected devices for respiratory therapies. These innovative solutions, equipped with sensors and wireless connectivity, facilitate comprehensive monitoring of medication adherence, usage patterns, and dosage accuracy. By harnessing mobile applications, patients can receive real-time feedback and personalized insights, enhancing their engagement and empowerment in managing their health. This shift towards data-driven solutions not only improves treatment outcomes but also fosters a more proactive approach to patient care, ultimately driving the market growth for connected drug delivery devices.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Startup Analysis

Global Connected Drug Delivery Devices Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Connected Inhalers
  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
• Connected Injection Devices
  • Connected Auto-Injectors
  • Connected Pen Injectors
  • Connected Wearable Injectors
• Connected Monitoring Devices
  • Smart Pills
  • Smart Patches

Global Connected Drug Delivery Devices Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Bluetooth
• Wi-Fi
• Near Field Communication (NFC)
• Others

Global Connected Drug Delivery Devices Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diabetes
  • Insulin Delivery
• Asthma & COPD
  • Bronchodilator Delivery
• Cardiovascular Diseases
  • Anticoagulant Delivery
• Other
  • Hormone Replacement Therapy
  • Pain Management

Global Connected Drug Delivery Devices Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
  • Large Hospitals
  • Small And Medium-Sized Hospitals
• Homecare Settings
  • Individual Patients
  • Caregivers
• Clinics
  • Specialty Clinics
  • General Clinics

Global Connected Drug Delivery Devices Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Application, End-User)
  • USA
  • Canada
• Europe (Product Type, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Findair Sp. z o. o. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIO CORP (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries Ltd (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adherium Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• West Pharmaceutical Services Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptar Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phillips-Medisize (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H&T Presspart Manufacturing Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cohero Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations